Abstract:Background Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.Methods We undertook an open-label, randomised, phase 3 trial at 22 centres in China. Patients older than 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin. Patients were randomly assigned (1:1) with a minimisation procedure and were stratified according to EGFR mutation type, histological subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status. The primary outcome was progression-free survival, analysed in patients with confirmed disease who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov, number NCT00874419, and has completed enrolment; patients are still in follow-up.Findings 83 patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in analysis of the primary endpoint. Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001). Chemotherapy was associated with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (three [4%] of 83 patients) and skin rash (two [2%] patients). Chemotherapy was also associated with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n=8; decreased neutrophil count, n=1; hepatic dysfunction, n=1] vs two [2%] of 83 patients [both hepatic dysfunction]).Interpretation Compared with standard chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-positive NSCLC and was associated with more favourable tolerability. These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC.

Sequential erlotinib in combination with chemotherapy in the treatment of advanced non-small cell lung cancer

Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-cell Lung Cancer

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-cell Lung Cancer.

Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer

Efficacy and Safety of Erlotinib in the Treatment for Advanced Non-Small Cell Lung Cancer in Chinese Patients

Preliminary Results Of Randomized Phase Iii Study Comparing Efficacy And Safety Of First-Line Erlotinib Versus Carboplatin (Cbdca) Plus Gemcitabine (Gem) In Chinese Advanced Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) With Egfr-Activating Mutations (Optimal)

Clinical Efficacy of Erlotinib in Patients Previously Treated for Advanced Non‐small Cell Lung Cancer

Efficacy of erlotinib plus best supportive care in treatment of advanced non-small cell lung cancer

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Clinical Efficacy of Toremifene Combined with Second Line Drugs Novelbine/cisplatin on Advanced Non-Small Cell Lung Cancer

Second-line therapy of erlotinib in advanced non-small cell lung cancer

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

Erlotinib Versus Chemotherapy As First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802): a Multicentre, Open-Label, Randomised, Phase 3 Study

Efficacy and Safety of Erlotinib on Advanced Non-small Cell Lung Cancer

P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib As a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Intercalated Combination of Chemotherapy and Erlotinib for Stage IIIA Non-Small-cell Lung Cancer: a Multicenter, Open-Label, Single-Arm, Phase II Study

Evaluation of erlotinib as a salvage treatment for non-small-cell lung cancer(NSCLC)patients after gefitinib failure

The evaluations of advanced non-small cell lung cancer patients treated with erlotnib

[Efficacy and Safety of Erlotinib As Monotherapy for Advanced Non-Small Cell Lung Cancer].